The Blood Screening Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Reagents & Kits, Instruments), By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA), Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting, Others), By End-User (Blood Banks, Hospitals, Others).
Blood screening is a systematic process of testing donated blood and blood products for infectious agents, such as viruses, bacteria, and parasites, to ensure the safety of transfusion recipients and reduce the risk of transfusion-transmitted infections (TTIs). In 2025, the importance of blood screening remains paramount, particularly with emerging infectious diseases, global travel, and the ongoing threat of pandemics. By employing sensitive and specific screening assays, including nucleic acid testing (NAT), enzyme-linked immunosorbent assays (ELISA), and chemiluminescent immunoassays (CLIA), blood centers and transfusion services can detect a wide range of pathogens, including HIV, hepatitis viruses, and emerging pathogens such as Zika virus and SARS-CoV-2. Moreover, with advancements in automation, multiplexing, and high-throughput screening platforms, blood screening laboratories can process large volumes of samples efficiently, ensuring a safe and adequate blood supply for patients in need. By implementing stringent quality control measures, donor eligibility criteria, and risk mitigation strategies, blood screening programs play a crucial role in preventing transfusion-related complications, safeguarding public health, and maintaining the integrity of the blood supply chain.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments across Abbott Laboratories Inc, Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories Inc, Danaher Corp, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Grifols S.A., Hologic Inc, Thermo Fisher Scientific Inc
A significant trend in the blood screening market is the implementation of advanced screening technologies for detecting infectious diseases and ensuring blood safety. Traditional screening methods, such as enzyme-linked immunosorbent assays (ELISA) and nucleic acid testing (NAT), have been the cornerstone of blood screening for decades. However, there is a growing emphasis on adopting more sensitive, specific, and high-throughput screening technologies to address emerging infectious threats and improve detection capabilities. Advanced screening technologies, such as next-generation sequencing (NGS), multiplex immunoassays, and molecular diagnostics platforms, offer enhanced sensitivity and specificity for detecting a wide range of pathogens, including viruses, bacteria, and parasites, in blood donations. The implementation of these advanced screening technologies reflects a commitment to ensuring the safety and integrity of the blood supply chain, driving innovation and growth in the blood screening market.
The primary driver fueling the growth of the blood screening market is the increasing demand for safe blood products to support transfusion therapy and medical procedures worldwide. Blood transfusions are essential for treating patients with various medical conditions, including trauma, surgery, cancer, and chronic diseases. However, the transfusion of contaminated blood products can transmit infectious diseases, such as HIV, hepatitis B, and hepatitis C, posing serious risks to patient health. As a result, there is stringent regulatory oversight and quality assurance measures in place to ensure the safety and purity of blood donations. Blood screening plays a crucial role in identifying infectious pathogens and screening out potentially contaminated blood units before they are transfused to patients, preventing transfusion-transmitted infections and safeguarding public health. With increasing awareness of the importance of blood safety and the growing demand for blood products, the need for robust and reliable blood screening technologies continues to drive market growth and innovation in blood screening assays, instruments, and consumables.
A potential opportunity for the blood screening market lies in the expansion into emerging markets and blood donor screening initiatives. While blood screening technologies are well-established in developed countries, there is still a need to improve access to safe blood products in low- and middle-income countries, where infectious diseases pose significant public health challenges. By expanding into emerging markets, blood screening companies can address unmet needs, enhance blood safety practices, and support the establishment of sustainable blood supply chains in resource-limited settings. Additionally, there is an opportunity to strengthen blood donor screening programs by implementing comprehensive screening protocols, donor questionnaires, and deferral criteria to minimize the risk of transmitting infectious diseases through blood donations. By investing in technology innovation, capacity building, and public health partnerships, blood screening providers can contribute to improving blood safety standards, reducing transfusion-transmitted infections, and saving lives around the world.
The fastest-growing segment in the Blood Screening Market is Instruments, driven by several factors contributing to the increasing demand for advanced screening technologies and equipment. With the growing emphasis on blood safety and the prevention of transfusion-transmitted infections, blood banks, hospitals, and other healthcare facilities are increasingly investing in state-of-the-art screening instruments to enhance the efficiency, accuracy, and throughput of blood screening processes. Technological advancements, such as automation, multiplexing capabilities, and high-throughput screening systems, enable faster and more comprehensive screening of donated blood for infectious agents like HIV, hepatitis B and C viruses, and syphilis, among others. Moreover, the rising demand for point-of-care testing and decentralized blood screening facilities further drives the adoption of compact, user-friendly instruments suitable for use in diverse healthcare settings. As a result, the Instruments segment experiences robust growth as healthcare institutions prioritize investments in advanced screening technologies to ensure the safety and quality of blood products.
The US Blood Screening Market size is estimated at $1088 Million in 2025. The U.S. blood screening market is driven by stringent regulatory frameworks, rising demand for early disease detection, and a high prevalence of transfusion-transmissible infections (TTIs). The Food and Drug Administration (FDA) mandates rigorous blood safety protocols, requiring blood banks and hospitals to implement nucleic acid testing (NAT), serological assays, and next-generation sequencing (NGS) technologies to detect pathogens like HIV, hepatitis B and C, and emerging threats such as Zika virus. Additionally, the increasing demand for plasma-derived therapies and personalized medicine is fueling the adoption of advanced screening techniques. However, challenges such as high testing costs, regulatory complexities, and workforce shortages in laboratory medicine could impact market growth. Future trends will include AI-driven blood screening automation, wider adoption of multiplex testing platforms, and enhanced research into pathogen-reduction technologies to further improve blood supply safety.
Europe Blood Screening Market continues to offer significant business potential with $928 Million sales revenue in 2025. Europe’s blood screening market is shaped by stringent health regulations under the European Medicines Agency (EMA) and national health agencies, driving the adoption of cutting-edge diagnostic technologies. Countries like Germany, France, and the UK have well-established blood donation programs and stringent safety protocols, ensuring high screening accuracy for TTIs. The push towards self-sufficiency in blood and plasma supply—combined with the increasing prevalence of chronic diseases requiring frequent transfusions—continues to support market growth. However, challenges such as the high cost of compliance with evolving regulatory standards under the EU Medical Device Regulation (MDR) and budget constraints in public healthcare systems may slow adoption of advanced screening technologies. Future market trends will focus on integrating artificial intelligence for predictive analytics in donor screening, expanding point-of-care blood screening solutions, and increasing research into non-invasive blood diagnostics.
South East Asia is among the fastest growing regions worldwide for Blood Screening Market. Over the forecast period to 2034, South East Asia Blood Screening Market demand is poised to register a robust growth rate of 10.4%. The blood screening market in Southeast Asia is growing due to the rising demand for safe blood transfusions, expanding healthcare infrastructure, and increasing prevalence of infectious diseases such as dengue and hepatitis. Countries like Singapore, Malaysia, and Thailand have strong government-backed blood donation programs, while emerging economies such as Indonesia and Vietnam are investing in upgrading screening facilities. However, the market faces challenges including inconsistent regulatory enforcement, limited access to high-end diagnostic technologies, and financial constraints in public hospitals that may delay adoption of advanced screening solutions. Future trends will include increased public-private partnerships to modernize blood banks, localized production of cost-effective screening kits, and greater adoption of rapid screening assays for real-time blood safety assessment.
Saudi Arabia’s blood screening market is expanding due to government initiatives under Vision 2030, increasing investments in healthcare modernization, and a strong emphasis on blood safety for both transfusions and surgical procedures. The country’s centralized healthcare system and growing number of blood banks—particularly within military and tertiary hospitals—are fostering demand for NAT, enzyme-linked immunosorbent assay (ELISA), and molecular diagnostic technologies. Additionally, religious and cultural encouragement of blood donation has led to a steady donor base, further driving the need for advanced screening tools. However, market challenges include the high cost of imported screening technologies, the need for skilled laboratory personnel, and logistical hurdles in ensuring uniform screening quality across remote regions. Future growth will be driven by increased automation in blood testing, adoption of blockchain for secure donor data management, and advancements in AI-driven screening analytics for enhanced infection detection.
|
Parameter |
Details |
|
Market Size (2025) |
$3.2 Billion |
|
Market Size (2034) |
$8.1 Billion |
|
Market Growth Rate |
10.9% |
|
Segments |
By Product (Reagents & Kits, Instruments), By Technology (Nucleic Acid Amplification Test (NAT), ELISA, Chemiluminescence Immunoassay (CLIA), Enzyme Immunoassay (EIA), Next Generation Sequencing (NGS), Western Blotting, Others), By End-User (Blood Banks, Hospitals, Others) |
|
Study Period |
2019- 2024 and 2025-2034 |
|
Units |
Revenue (USD) |
|
Qualitative Analysis |
Porter’s Five Forces, SWOT Profile, Market Share, Scenario Forecasts, Market Ecosystem, Company Ranking, Market Dynamics, Industry Benchmarking |
|
Companies |
Abbott Laboratories Inc, Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories Inc, Danaher Corp, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Grifols S.A., Hologic Inc, Thermo Fisher Scientific Inc |
|
Countries |
US, Canada, Mexico, Germany, France, Spain, Italy, UK, Russia, China, India, Japan, South Korea, Australia, South East Asia, Brazil, Argentina, Middle East, Africa |
By Product
By Technology
By End-User
Geographical Analysis
*List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Blood Screening Market, encompassing current market size, growth trends, and forecasts till 2034.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Blood Screening Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Blood Screening Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Blood Screening Market Size Outlook, $ Million, 2021 to 2030
3.2 Blood Screening Market Outlook by Type, $ Million, 2021 to 2030
3.3 Blood Screening Market Outlook by Product, $ Million, 2021 to 2030
3.4 Blood Screening Market Outlook by Application, $ Million, 2021 to 2030
3.5 Blood Screening Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Blood Screening Industry
4.2 Key Market Trends in Blood Screening Industry
4.3 Potential Opportunities in Blood Screening Industry
4.4 Key Challenges in Blood Screening Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Blood Screening Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Blood Screening Market Outlook by Segments
7.1 Blood Screening Market Outlook by Segments, $ Million, 2021- 2030
By Product
Reagents & Kits
Instruments
By Technology
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA)
Enzyme Immunoassay (EIA)
Next Generation Sequencing (NGS)
Western Blotting
Others
By End-User
Blood Banks
Hospitals
Others
8 North America Blood Screening Market Analysis and Outlook To 2030
8.1 Introduction to North America Blood Screening Markets in 2024
8.2 North America Blood Screening Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Blood Screening Market size Outlook by Segments, 2021-2030
By Product
Reagents & Kits
Instruments
By Technology
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA)
Enzyme Immunoassay (EIA)
Next Generation Sequencing (NGS)
Western Blotting
Others
By End-User
Blood Banks
Hospitals
Others
9 Europe Blood Screening Market Analysis and Outlook To 2030
9.1 Introduction to Europe Blood Screening Markets in 2024
9.2 Europe Blood Screening Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Blood Screening Market Size Outlook by Segments, 2021-2030
By Product
Reagents & Kits
Instruments
By Technology
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA)
Enzyme Immunoassay (EIA)
Next Generation Sequencing (NGS)
Western Blotting
Others
By End-User
Blood Banks
Hospitals
Others
10 Asia Pacific Blood Screening Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Blood Screening Markets in 2024
10.2 Asia Pacific Blood Screening Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Blood Screening Market size Outlook by Segments, 2021-2030
By Product
Reagents & Kits
Instruments
By Technology
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA)
Enzyme Immunoassay (EIA)
Next Generation Sequencing (NGS)
Western Blotting
Others
By End-User
Blood Banks
Hospitals
Others
11 South America Blood Screening Market Analysis and Outlook To 2030
11.1 Introduction to South America Blood Screening Markets in 2024
11.2 South America Blood Screening Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Blood Screening Market size Outlook by Segments, 2021-2030
By Product
Reagents & Kits
Instruments
By Technology
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA)
Enzyme Immunoassay (EIA)
Next Generation Sequencing (NGS)
Western Blotting
Others
By End-User
Blood Banks
Hospitals
Others
12 Middle East and Africa Blood Screening Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Blood Screening Markets in 2024
12.2 Middle East and Africa Blood Screening Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Blood Screening Market size Outlook by Segments, 2021-2030
By Product
Reagents & Kits
Instruments
By Technology
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA)
Enzyme Immunoassay (EIA)
Next Generation Sequencing (NGS)
Western Blotting
Others
By End-User
Blood Banks
Hospitals
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories Inc
Becton, Dickinson and Company
bioMérieux S.A.
Bio-Rad Laboratories Inc
Danaher Corp
DiaSorin S.p.A.
F. Hoffmann-La Roche Ltd
Grifols S.A.
Hologic Inc
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
Reagents & Kits
Instruments
By Technology
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA)
Enzyme Immunoassay (EIA)
Next Generation Sequencing (NGS)
Western Blotting
Others
By End-User
Blood Banks
Hospitals
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The Global Blood Screening Market Size is estimated at $3.2 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.9% to reach $8.1 Billion by 2034.
The US Blood Screening Market size is estimated at $1088 Million in 2025.
Abbott Laboratories Inc, Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories Inc, Danaher Corp, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Grifols S.A., Hologic Inc, Thermo Fisher Scientific Inc
Base Year- 2024; Estimated Year- 2025; Historic Period- 2019-2024; Forecast period- 2025 to 2034; Currency: Revenue (USD); Volume
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.